The trial showed a trend towards reduced incidence of IAPA in the posaconazole arm versus the placebo arm (5.4% versus 11.1%), but failed to prove statistical significance, because of lack of power and due to the fact that the rate of early IAPA after ICU admission (within 48 h) was higher than expected.
← all excerpts
COVID-19 associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit: Impact of Antifungal Prophylaxis.
1
—
—